Canaan Partners XI LLC Has $38.55 Million Stock Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Canaan Partners XI LLC cut its position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 0.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,144,590 shares of the company's stock after selling 35,267 shares during the quarter. Tyra Biosciences makes up 58.1% of Canaan Partners XI LLC's investment portfolio, making the stock its largest position. Canaan Partners XI LLC owned about 7.81% of Tyra Biosciences worth $38,545,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of TYRA. Rhumbline Advisers raised its holdings in Tyra Biosciences by 4.1% in the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company's stock valued at $364,000 after acquiring an additional 1,027 shares in the last quarter. RA Capital Management L.P. increased its stake in Tyra Biosciences by 2.1% during the fourth quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company's stock valued at $147,858,000 after purchasing an additional 220,681 shares during the last quarter. Deutsche Bank AG grew its position in shares of Tyra Biosciences by 52.0% during the fourth quarter. Deutsche Bank AG now owns 18,909 shares of the company's stock worth $263,000 after acquiring an additional 6,466 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Tyra Biosciences during the fourth quarter worth about $761,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Tyra Biosciences by 283.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 37,981 shares of the company's stock worth $528,000 after acquiring an additional 28,074 shares during the last quarter. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Tyra Biosciences Stock Up 6.3%

Shares of NASDAQ:TYRA traded up $0.61 during trading on Wednesday, reaching $10.26. The stock had a trading volume of 832,093 shares, compared to its average volume of 271,091. Tyra Biosciences, Inc. has a 52 week low of $6.42 and a 52 week high of $29.60. The firm has a market capitalization of $544.70 million, a price-to-earnings ratio of -6.37 and a beta of 1.17. The stock has a fifty day simple moving average of $9.25 and a two-hundred day simple moving average of $12.26.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. On average, analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Analyst Ratings Changes

TYRA has been the subject of several recent research reports. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Tyra Biosciences in a research report on Monday, March 31st. Piper Sandler initiated coverage on shares of Tyra Biosciences in a research note on Wednesday, May 21st. They set an "overweight" rating and a $33.00 target price on the stock. Finally, Wedbush reissued an "outperform" rating and set a $30.00 target price on shares of Tyra Biosciences in a research note on Friday, March 28th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $30.83.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.